NCT04108091View on ClinicalTrials.gov

Vyndaqel Capsules Special Investigation (ATTR-CM)

CompletedOBSERVATIONAL
Enrollment

1,214

Participants

Timeline

Start Date

October 3, 2019

Primary Completion Date

March 27, 2025

Study Completion Date

March 27, 2025

Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
DRUG

Treatment for TTR amyloidosis

The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.

DRUG

Treatment for TTR amyloidosis

The usual adult dose is 61 mg of tafamidis orally once daily.

Trial Locations (1)

Unknown

Pfizer, Tokyo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04108091 - Vyndaqel Capsules Special Investigation (ATTR-CM) | Biotech Hunter | Biotech Hunter